Trial Profile
A Phase Ib Study of APL-1202 in NMIBC Patients Who Are Resistant to One Induction Course of BCG Treatment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; Nitroxoline (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- Acronyms NMIBC
- Sponsors Asieris Pharmaceuticals
- 16 Jul 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 21 Jun 2019 According to an Asieris Pharmaceuticals media release, John P. Sfakianos, MD, (Assistant Professor of Icahn School of Medicine at Mount Sinai) is the leading investigator of this trial.